About: Pleiotropic effect of Lactoferrin in the prevention and treatment of COVID-19 infection: randomized clinical trial, in vitro and in silico preliminary evidences

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pleiotropic effect of Lactoferrin in the prevention and treatment of COVID-19 infection: randomized clinical trial, in vitro and in silico preliminary evidences Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Pleiotropic effect of Lactoferrin in the prevention and treatment of COVID-19 infection: randomized clinical trial, in vitro and in silico preliminary evidences
Creator	Rosa, Luigi Ciotti, Marco Bernardini, Sergio Vecchio, Claudia Andreoni, Massimo Bartoletti, Pier Campione, Elena Chiaramonte, Carlo Conte, Maria Coppeda, Luca Cosio, Terenzio Falconi, Mattia Franchin, Elisa Iacovelli, Iannuzzi, Ilaria Lanna, Caterina Lia, Luca Bianchi, § Magrini, Andrea Minieri, Marilena Moricca, Nicola Nuccetelli, Marzia Romeo, Alice Rosapepe, Felice Sabatini, Stefano Stella, Maria Terrinoni, Valenti,
Source	BioRxiv
abstract	The current treatments against SARS-CoV-2 have proved so far inadequate. A potent antiviral drug is yet to be discovered. Lactoferrin, a multifunctional glycoprotein, secreted by exocrine glands and neutrophils, possesses an antiviral activity extendable to SARS-Cov-2. We performed a randomized, prospective, interventional study assessing the role of oral and intra-nasal lactoferrin to treat mild-to-moderate and asymptomatic COVID-19 patients to prevent disease evolution. Lactoferrin induced an early viral clearance and a fast clinical symptoms recovery in addition to a statistically significant reduction of D-Dimer, Interleukin-6 and ferritin blood levels. The antiviral activity of lactoferrin related to its binding to SARS-CoV-2 and cells and protein-protein docking methods, provided the direct recognition between lactoferrin and spike S, thus hindering the spike S attachment to the human ACE2 receptor and consequently virus entering into the cells. Lactoferrin can be used as a safe and efficacious natural agent to prevent and treat COVID-19 infection.
has issue date	2020-08-17(xsd:dateTime)
bibo:doi	10.1101/2020.08.11.244996
has license	biorxiv
sha1sum (hex)	4ae53029b955fc7de9832089eeb5fc51973623ec
schema:url	https://doi.org/10.1101/2020.08.11.244996
resource representing a document's title	Pleiotropic effect of Lactoferrin in the prevention and treatment of COVID-19 infection: randomized clinical trial, in vitro and in silico preliminary evidences
schema:publication	bioRxiv
resource representing a document's body	covid:4ae53029b955fc7de9832089eeb5fc51973623ec#body_text
is schema:about of	named entity 'efficacious' named entity 'glycoprotein' named entity 'statistically' named entity 'SARS-CoV-2' named entity 'antiviral drug' named entity 'virus' named entity 'neutrophils' named entity 'binding' named entity 'study' named entity 'nasal' named entity 'potent' named entity 'activity' named entity 'early' named entity 'intra' named entity 'asymptomatic' named entity 'infection' named entity 'Lactoferrin' named entity 'evolution' named entity 'kilobases' named entity 'blood levels' named entity 'neutrophils' named entity 'antiviral activity' named entity 'glycoprotein' named entity 'COVID' named entity 'viral' named entity 'COVID' named entity 'immune responses' named entity 't-test' named entity '0.01' named entity 'inoculum' named entity '0.01' named entity 'hpi' named entity 'PDB' named entity 'supernatants' named entity 'asymptomatic patients' named entity 'viral load' named entity 'ACE2 receptor' named entity 'infection' named entity 'hydrophobic contacts' named entity 'hpi' named entity 'hpi' named entity 'Liver' named entity 'SARS-CoV-2' named entity 'asymptomatic' named entity '11.5' named entity 'hpi' named entity 'ACE2' named entity 'antiviral' named entity 'HSPGs' named entity 'protein' named entity 'conformation' named entity 'virus infection' named entity '0.01' named entity 'control group' named entity 'protein' named entity '37°C' named entity 'virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software